Pharmaceutical giant Johnson & Johnson (JNJ) is planning to sell its stroke care business called “Cerenovus” for $1 billion ...

Johnson & Johnson (NYSE:JNJ) is a healthcare company engaged in the research, development, manufacturing, and marketing of a ...

Compared to the aggregate P/E ratio of the 27.1 in the Pharmaceuticals industry, Johnson & Johnson Inc. has a lower P/E ratio ...

Johnson & Johnson is considering selling its stroke care unit, Cerenovus, in a potential $1 billion deal as part of its ...

Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently sold shares of the company's stock. According to a recent SEC filing, Wolk sold 13,015 ...

Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (NYSE:JNJ), recently executed significant stock transactions according to a recent SEC filing. On February 7, ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has earned a consensus rating of “Buy” from the nine ...

Johnson & Johnson is putting its stroke care business up for sale as the company aims to reorganize and rebuild its medtech unit, the ...

Johnson Controls is well-positioned with a robust $13.2 billion backlog and AI-driven solutions. Read what makes JCI stock an ...